Home  |  Site Map  |  Contact Us  |  
Search

   
   

Ronald W. Barrett, Ph.D. | Chief Executive Officer and Director
Vincent J. Angotti | Executive Vice President and Chief Operating Officer
Gregory T. Bates, D.V.M. | Senior Vice President of Regulatory Affairs and Quality
Gianna M. Bosko | Senior Vice President, Chief Legal Officer and Secretary
Kenneth C. Cundy, Ph.D. | Chief Scientific Officer
William G. Harris | Senior Vice President of Finance and Chief Financial Officer
Richard K. Kim, M.D. | Senior Vice President, Clinical Development and Medical Affairs, and Chief Medical Officer
David R. Savello, Ph.D. | Senior Vice President of Development Operations
Peter A. Virsik | Senior Vice President of Corporate Development

 

Ronald W. Barrett, Ph.D.
Chief Executive Officer and Director

Ronald W. Barrett is one of our founders and has served as our chief executive officer since September 2001. He served as our chief scientific officer from 1999 to 2001. Dr. Barrett has been a director since August 1999. From 1989 to 1999, he held various positions at Affymax Research Institute, the most recent of which was senior vice president of research (acquired by Glaxo Welcome plc, now known as GSK, in 1995). Prior to Affymax Research Institute, Dr. Barrett was a molecular pharmacologist in the Neuroscience Group at Abbott Laboratories from 1986 to 1989. Dr. Barrett received a B.S. from Bucknell University and a Ph.D. in pharmacology from Rutgers University.


Vincent J. Angotti
Executive Vice President and Chief Operating Officer

Vincent J. Angotti has been our executive vice president and chief operating officer since June 2012. He was previously senior vice president and chief commercialization officer from May 2008 to June 2012. From 2001 to 2008, he held several positions with Reliant Pharmaceuticals, Inc., the most recent of which was senior vice president of sales and marketing. GlaxoSmithKline acquired Reliant Pharmaceuticals in 2008. Prior to Reliant Pharmaceuticals, from 1991 to 2001, Mr. Angotti held several positions at Novartis Pharmaceuticals Corporation, most recently as executive director, field operations. Mr. Angotti received a B.S. from Cornell University and an M.B.A. from Columbia University.


Gregory T. Bates, D.V.M.
Senior Vice President of Regulatory Affairs and Quality

Dr. Bates has been our senior vice president of regulatory affairs and quality since June 2012. He was previously our vice president of regulatory affairs from 2006 to June 2012. From 1998 to 2006, Dr. Bates held various positions at Pharmacyclics, Inc, the most recent of which was senior director of regulatory affairs. Prior to Pharmacyclics, in 1998, Dr. Bates was director of regulatory affairs and quality at Otsuka America Pharmaceutical, Inc. From 1995 to 1998, he was manager of regulatory affairs at Genentech, Inc., and from 1990 to 1995, he was senior manager of agribusiness regulatory affairs at Syntex (USA), Inc. Dr. Bates received a B.A. from the University of California, Berkeley and a Doctor of Veterinary Medicine from the University of California, Davis.


Gianna M. Bosko
Senior Vice President, Chief Legal Officer and Secretary

Gianna M. Bosko has been our senior vice president, chief legal officer and secretary since April 2013. She was previously our senior vice president, chief administrative officer, general counsel and secretary from August 2010 to April 2013. Prior to that she was our vice president, general counsel and secretary from 2007 to 2010, and senior corporate counsel from 2005 to 2007. From 2004 to 2005, Ms. Bosko was a legal consultant, providing general corporate and in-house legal consulting services for private and public companies, including XenoPort. From 1996 to 2004, she was an associate at Cooley LLP, practicing general corporate and securities law, with an emphasis on securities transactions and mergers and acquisitions. Ms. Bosko received an A.B. from Stanford University and a J.D. from the University of Chicago Law School.


Kenneth C. Cundy, Ph.D.
Chief Scientific Officer

Kenneth C. Cundy has been our chief scientific officer since December 2012. From 2011 to 2012, he was senior vice president of preclinical and clinical sciences. Dr. Cundy served as our vice president of preclinical development from 2004 to 2011 and as vice president of biopharmaceutics from 2000 to 2004. From 1992 to 2000, Dr. Cundy was senior director of biopharmaceutics at Gilead Sciences, Inc. Prior to Gilead Sciences, from 1988 to 1992 Dr. Cundy was principal research investigator at Sterling Drug, a pharmaceutical division of Eastman Kodak Company. He received a B.S. in pharmacy from the University of Manchester and was registered as a pharmacist in the UK. He received a Ph.D. in pharmaceutical sciences from the University of Kentucky and postdoctoral training at the University of California, Berkeley.


William G. Harris
Senior Vice President of Finance and Chief Financial Officer

William G. Harris has been our senior vice president of finance and chief financial officer since 2001. From 1996 to 2001, he held several positions with Coulter Pharmaceutical, Inc., the most recent of which was senior vice president and chief financial officer. Corixa Corp. acquired Coulter Pharmaceutical in 2000. Prior to Coulter Pharmaceutical, from 1990 to 1996, Mr. Harris held several positions at Gilead Sciences, Inc., most recently as director of finance. Mr. Harris received a B.A. from the University of California, San Diego and an M.B.A. from Santa Clara University, Leavey School of Business and Administration.


Richard K. Kim, M.D.
Senior Vice President, Clinical Development and Medical Affairs, and Chief Medical Officer

Richard K. Kim has been our senior vice president, clinical development and medical affairs, and chief medical officer since January 2014. He was previously our vice president of medical affairs from July 2013 to January 2014. From 2012 to 2013, Dr. Kim was vice president of clinical development and head of the multiple sclerosis therapeutic area, and from 2010 to 2012, he was senior director, clinical development at Elan Pharmaceuticals, Inc. Prior to that, from 2006 to 2010, Dr. Kim was global medical director, medical affairs at Biogen Idec Inc. From 2004 to 2006, he was medical director, clinical development for EMD Serono, Inc. Prior to that, he was associate medical director from 2002 to 2004 at Purdue Pharma L.P. Dr. Kim received a B.S. degree from University of California at Los Angeles and his M.D. from Tulane University. He completed his neurology residency training at Stanford University, and is currently a diplomat of the American Board of Psychiatry and Neurology.


David R. Savello, Ph.D.
Senior Vice President of Development Operations

David R. Savello has been our senior vice president of development operations since November 2010. He was previously our senior vice president of development from 2007 to November 2010. He was responsible for our regulatory affairs, quality and project management from 2005 to 2007. From 1999 to 2005, Dr. Savello was executive vice president and chief scientific officer for the Pharmaceutical Technology and Services Sector of Cardinal Health, Inc. Prior to joining Cardinal Health, from 1997 to 1999, he was senior vice president for drug development at Guilford Pharmaceuticals Inc. From 1985 to 1997, Dr. Savello held several positions at Glaxo and Glaxo Wellcome including both vice president of drug development and vice president of regulatory affairs and compliance. Prior to that, he held R&D management and executive management positions at Boehringer Ingelheim GmbH, and 3M Company. Dr. Savello received his B.S. degree from the Massachusetts College of Pharmacy and both an M.S. and a Ph.D. in pharmaceutics from the University of Maryland School of Pharmacy.


Peter A. Virsik
Senior Vice President of Corporate Development

Peter A. Virsik has been our senior vice president of corporate development since October 2013. He was previously our vice president of business development from January 2010 to October 2013 and executive director of business development from January 2008 to January 2010. Mr. Virsik joined XenoPort in 2005 as senior director of business development. Prior to joining XenoPort, from 2000 to 2005, Mr. Virsik was associate director of corporate development for Gilead Sciences, Inc. Prior to joining Gilead, in 1999 Mr. Virsik worked in the biotechnology equity research group at J.P. Morgan and from 1997 to 1998 as a consultant for Ernst and Young, LLP. From 1993 to 1995, Mr. Virsik was a research assistant at Genentech, Inc. Mr. Virsik received a B.A. from the University of California, Berkeley, an M.S. from the University of Michigan, Ann Arbor and an M.B.A. from the Kellogg Graduate School of Management at Northwestern University.


 

 
Corporate Governance

The reputation of our company and the success of our mission depend on the honesty and integrity of each and every one of us.